In recent years, the field of pharmaceutical sciences has witnessed tremendous progress in the development of novel therapeutics. One such promising candidate was lirentelimab, a drug developed by Allakos Inc., aimed at providing relief for patients suffering from atopic dermatitis and chronic spontaneous urticaria. However, despite initial optimism, the company recently announced that the Phase 2 trials of lirentelimab did not meet their primary endpoints. This article explores the implications of this setback for Allakos Inc., their decision to discontinue further development of lirentelimab, and their strategic focus on alternative clinical development programs.Background:Atopic dermatitis, commonly refer...

ALLK's Stock Performance relative to it's Customers

ALLK's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Allakos Inc	29.59	0.00	-70.85	131
SUBTOTAL	0.00	0.00	0.00	-

Sources: Allakos Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Allakos Inc’s corporate clients.
For your research, we’ve provided 9 tables on Allakos Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.